Cannabidiol, pharmaceutically produced with < 5 ppm THC
CARDIOL 100-03
Phase 3 small_molecule terminated
Quick answer
Cannabidiol, pharmaceutically produced with < 5 ppm THC for COVID-19 is a Phase 3 program (small_molecule) at Cardiol Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cardiol Therapeutics
- Indication
- COVID-19
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated